Sunil A Reddy, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Reddy’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A61643 · Current
Licensed to practise in California · since 1997 · expires 2028-08-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$146,585
Medicare paid this office $146,585 for 311 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 122 | $41,147 | $164 |
| Long return visit (40+ min) | 99 | $31,836 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $25,035 | $104 |
| Return visit (30+ min) | 58 | $14,937 | $86 |
| Return visit (30+ min) | 77 | $12,322 | $116 |
See all 9 services
| Long return visit (40+ min) | 122 | $41,147 | $164 |
| Long return visit (40+ min) | 99 | $31,836 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $25,035 | $104 |
| Return visit (30+ min) | 58 | $14,937 | $86 |
| Return visit (30+ min) | 77 | $12,322 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,110 | $153 |
| Hospital discharge day management, more than 30 minutes | 57 | $5,850 | $103 |
| New patient visit (60+ min) | 27 | $4,403 | $163 |
| Short return visit (20+ min) | 14 | $1,359 | $85 |
Who their Medicare patients are
311 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 13% · Women 39% · Also on Medicaid 19% · Health risk score 2.58. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 69% · Coronary heart disease 34% · Cancer 31% · Atrial fibrillation 30% · Diabetes 28% · Chronic kidney disease 28% · Depression 24% · Heart failure 20% · COPD 14% · Dementia 12% · Stroke 12%.
The office billed $574,698, Medicare allowed $189,679 and paid $146,585; for 1,208 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 311 | 1,208 | 75 | 2.58 | $574,698 | $146,585 |
| 2023 | 316 | 1,136 | 75 | 2.66 | $497,253 | $134,279 |
| 2022 | 351 | 1,146 | 75 | 2.55 | $507,783 | $132,261 |
| 2021 | 360 | 1,285 | 74 | 2.32 | $520,910 | $139,667 |
| 2020 | 256 | 1,006 | 74 | 2.50 | $358,324 | $88,694 |
| 2019 | 256 | 965 | 74 | 2.42 | $196,705 | $92,636 |
| 2018 | 257 | 925 | 73 | 2.26 | $201,376 | $87,297 |
| 2017 | 229 | 818 | 73 | 2.35 | $202,630 | $71,692 |
| 2016 | 212 | 586 | 73 | 2.56 | $170,503 | $53,212 |
| 2015 | 144 | 407 | 73 | 2.33 | $113,467 | $37,617 |
| 2014 | 143 | 347 | 71 | 1.66 | $99,534 | $32,678 |
| 2013 | 83 | 257 | 73 | 1.94 | $70,870 | $22,863 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 158 | $62,243 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $27,286 | $108 |
| Return visit (30+ min) | 107 | $19,921 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $9,756 | $160 |
| New patient visit (60+ min) | 54 | $8,571 | $159 |
| Hospital discharge day management, more than 30 minutes | 40 | $4,284 | $107 |
2022: 7 services
| Long return visit (40+ min) | 161 | $59,471 | $128 |
| Return visit (30+ min) | 97 | $19,710 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $17,174 | $93 |
| New patient visit (60+ min) | 72 | $12,509 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $12,500 | $181 |
| Hospital discharge day management, more than 30 minutes | 46 | $4,596 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,622 | $65 |
2021: 11 services
| Long return visit (40+ min) | 133 | $49,037 | $131 |
| Return visit (30+ min) | 115 | $25,892 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $22,224 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $11,031 | $184 |
| New patient visit (60+ min) | 55 | $9,299 | $169 |
| Hospital discharge day management, more than 30 minutes | 52 | $5,303 | $100 |
| Long return visit (40+ min) | 23 | $3,650 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,402 | $67 |
| Short return visit (20+ min) | 35 | $3,159 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,378 | $125 |
| Return visit (30+ min) | 11 | $1,013 | $68 |
2020: 10 services
| Long return visit (40+ min) | 124 | $25,333 | $96 |
| Return visit (30+ min) | 110 | $22,696 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $11,640 | $98 |
| New patient visit (60+ min) | 51 | $7,842 | $154 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $6,307 | $191 |
| Short return visit (20+ min) | 41 | $3,180 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,945 | $67 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,554 | $102 |
| Return visit (30+ min) | 17 | $1,860 | $93 |
| Telehealth originating site facility fee | 14 | $362 | $20 |
2019: 8 services
| Long return visit (40+ min) | 145 | $46,745 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $11,886 | $94 |
| Return visit (30+ min) | 55 | $9,047 | $67 |
| New patient visit (60+ min) | 59 | $8,691 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,443 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,508 | $66 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,182 | $99 |
| Short return visit (20+ min) | 15 | $1,161 | $45 |
2018: 10 services
| Long return visit (40+ min) | 121 | $33,989 | $98 |
| Return visit (30+ min) | 74 | $12,433 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $12,077 | $94 |
| New patient visit (60+ min) | 55 | $8,135 | $148 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,301 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,399 | $65 |
| Hospital discharge day management, more than 30 minutes | 29 | $2,963 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,322 | $122 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,270 | $67 |
| Short return visit (20+ min) | 12 | $1,014 | $46 |
2017: 9 services
| Return visit (30+ min) | 96 | $19,639 | $68 |
| Long return visit (40+ min) | 74 | $15,797 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $9,909 | $93 |
| New patient visit (60+ min) | 51 | $7,379 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,983 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,405 | $65 |
| Hospital discharge day management, more than 30 minutes | 31 | $3,142 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,587 | $122 |
| Short return visit (20+ min) | 19 | $1,278 | $44 |
2016: 8 services
| Long return visit (40+ min) | 69 | $11,713 | $95 |
| Return visit (30+ min) | 75 | $10,635 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $8,241 | $93 |
| New patient visit (60+ min) | 54 | $8,050 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,768 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,472 | $64 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,459 | $97 |
| Hospital discharge day management, 30 minutes or less | 11 | $723 | $66 |
2015: 6 services
| Long return visit (40+ min) | 64 | $15,659 | $96 |
| Return visit (30+ min) | 52 | $7,170 | $67 |
| New patient visit (60+ min) | 30 | $4,479 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,983 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,985 | $93 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,269 | $98 |
2014: 5 services
| Long return visit (40+ min) | 57 | $12,313 | $93 |
| Return visit (30+ min) | 63 | $7,868 | $69 |
| New patient visit (60+ min) | 45 | $6,214 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,597 | $180 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,062 | $97 |
2013: 3 services
| Long return visit (40+ min) | 54 | $15,290 | $91 |
| New patient visit (60+ min) | 30 | $4,127 | $138 |
| Return visit (30+ min) | 21 | $2,448 | $66 |
Medicaid work
$7,050 in 2024
Medicaid paid $7,050 for 90 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 90 | $7,050 |
| 2024 | 90 | 1 | 13 | $7,050 |
| 2023 | 216 | 4 | 25 | $9,862 |
| 2022 | 168 | 1 | 14 | $8,034 |
| 2021 | 123 | 3 | 20 | $4,169 |
| 2020 | 44 | 2 | 13 | $1,857 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 140 | $5,471 |
| Long return visit (40+ min) | 51 | $3,131 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $677 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $583 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 168 | $8,034 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 93 | $3,124 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $558 |
| Return visit (30+ min) | 17 | $486 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $1,211 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 12 | $645 |
Drugs they prescribed that Part D paid
$103,980
Pharmacies billed $103,980 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 17% of their Part D prescriptions (25 of 148) in 2024. A higher opioid share than 9 in 10 peers; the typical medical oncology clinician is at 6%.
128 generic and 20 brand-name prescriptions · $103,980 in drug cost · 20 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Levothyroxine | 18 | $200 | $11 |
| Oxycodone | 12 | $100 | $8 |
| Prednisone | 14 | $38 | $3 |
Year by year
| 2024 | 148 | 49 | 17% (25) | 14% | $103,980 |
| 2023 | 111 | 39 | None | None | $52,101 |
| 2022 | 121 | 42 | None | None | $10,844 |
| 2021 | 125 | 44 | 10% (12) | 32% | $10,200 |
| 2020 | 189 | 45 | None | None | $26,153 |
| 2019 | 172 | 51 | None | 48% | $328,318 |
| 2018 | 255 | 75 | 6% (16) | 23% | $204,169 |
| 2017 | 307 | 62 | 7% (22) | 31% | $643,100 |
| 2016 | 196 | 52 | None | 42% | $603,023 |
| 2015 | 190 | 40 | 7% (14) | 32% | $427,974 |
| 2014 | 153 | 44 | 9% (14) | 23% | $203,962 |
| 2013 | 139 | 25 | 19% (26) | 13% | $42,582 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Prednisone | 25 | $107 | $4 |
2022: 2 drugs
| Prednisone | 17 | $93 | $5 |
| Levothyroxine | 11 | $66 | $6 |
2021: 1 drug
| Levothyroxine | 37 | $656 | $18 |
2020: 4 drugs
| Levothyroxine | 39 | $626 | $16 |
| Prednisone | 29 | $324 | $11 |
| Hydrocortisone | 12 | $267 | $22 |
| Sulfamethoxazole-Trimethoprim | 16 | $46 | $3 |
2019: 4 drugs
| Mekinist | 11 | $129,506 | $11,773 |
| Hydrocortisone | 14 | $352 | $25 |
| Levothyroxine | 18 | $220 | $12 |
| Prednisone | 26 | $159 | $6 |
2018: 7 drugs
| Tafinlar | 14 | $141,285 | $10,092 |
| Hydrocortisone | 18 | $526 | $29 |
| Valacyclovir | 14 | $436 | $31 |
| Levothyroxine | 15 | $284 | $19 |
| Prednisone | 24 | $187 | $8 |
| Pantoprazole | 12 | $85 | $7 |
| Atorvastatin | 12 | $73 | $6 |
2017: 5 drugs
| Mekinist | 27 | $312,163 | $11,562 |
| Tafinlar | 27 | $281,347 | $10,420 |
| Hydrocortisone | 12 | $513 | $43 |
| Levothyroxine | 21 | $496 | $24 |
| Prednisone | 30 | $174 | $6 |
2016: 5 drugs
| Mekinist | 28 | $288,151 | $10,291 |
| Tafinlar | 29 | $268,064 | $9,244 |
| Enoxaparin | 11 | $7,940 | $722 |
| Hydrocortisone | 17 | $713 | $42 |
| Levothyroxine | 13 | $97 | $7 |
2015: 5 drugs
| Mekinist | 22 | $224,966 | $10,226 |
| Tafinlar | 22 | $196,538 | $8,934 |
| Hydrocortisone | 11 | $343 | $31 |
| Prednisone | 19 | $302 | $16 |
| Levothyroxine | 11 | $118 | $11 |
2014: 2 drugs
| Mekinist | 12 | $116,099 | $9,675 |
| Prednisone | 14 | $132 | $9 |
2013: 1 drug
| Lorazepam | 11 | $77 | $7 |
Money from drug and device companies
$1,785 in 2025
| 2025 | 6 | 17 | $208 | $1,785 |
| 2024 | 3 | 11 | None | $385 |
| 2023 | 5 | 12 | None | $507 |
| 2022 | 2 | 3 | None | $295 |
| 2021 | 1 | 1 | None | $88 |
| 2020 | 3 | 6 | $960 | $1,060 |
| 2019 | 4 | 33 | None | $836 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Immunocore | Kimmtrak | $1,145 | 3 payments
|
| Taiho Oncology | None | $207 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $141 | 3 payments
|
| Pfizer | Nurtec Odt | $125 | 5 payments
|
| Regeneron Pharmaceuticals | Libtayo | $116 | 1 payment
|
| Celgene | Zeposia | $51 | 2 payments
|
See all 17 published payments
| Celgene | Meals · 2025-12-15 | Zeposia | $30 |
| Immunocore | Meals · 2025-11-14 | Kimmtrak | $100 |
| Celgene | Meals · 2025-11-10 | Zeposia | $21 |
| Immunocore | Meals · 2025-10-17 | Kimmtrak | $101 |
| Regeneron Pharmaceuticals | Meals · 2025-06-26 | Libtayo | $116 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-05-31 | None | $32 |
| Taiho Oncology | Travel · 2025-05-31 | None | $47 |
| Pfizer | Meals · 2025-05-02 | Nurtec Odt | $26 |
| Immunocore | Travel · 2025-04-23 | Kimmtrak | $944 |
| Pfizer | Meals · 2025-04-04 | Nurtec Odt | $28 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-29 | None | $84 |
| Taiho Oncology | Paid to speak or teach · 2025-03-29 | None | $124 |
| Pfizer | Meals · 2025-03-07 | Nurtec Odt | $26 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-02-14 | None | $25 |
| Taiho Oncology | Travel · 2025-02-14 | None | $37 |
| Pfizer | Meals · 2025-02-14 | Nurtec Odt | $25 |
| Pfizer | Meals · 2025-01-29 | Panzyga | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $385
| Pfizer | Nurtec Odt | $231 | 9 payments
|
| Delcath Systems | Hepzato Kit | $140 | 1 payment
|
| Array Biopharma | Braftovi | $14 | 1 payment
|
2023: $507
| Galvanize Therapeutics | Aliya System | $221 | 1 payment
|
| Pfizer | Nurtec Odt | $145 | 8 payments
|
| TriSalus Life Sciences | Trinav Infusion System | $101 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
| Array Biopharma | Braftovi | $18 | 1 payment
|
2022: $295
| E.R. Squibb & Sons L.L.C. | Opdivo | $186 | 2 payments
|
| Immunocore | Kimmtrak | $109 | 1 payment
|
2021: $88
| E.R. Squibb & Sons L.L.C. | Opdivo | $88 | 1 payment
|
2020: $1,060
| Varian Medical Systems | None | $960 | 1 payment
|
| EMD Serono | Mavenclad | $76 | 4 payments
|
| Eisai | Lenvima | $24 | 1 payment
|
2019: $836
| EMD Serono | Mavenclad | $372 | 29 payments
|
| Array BioPharma | Braftovi | $160 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $157 | 2 payments
|
| Novocure | Oncology | $147 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2024 | Their institution | $353,806 |
| TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2023 | Their institution | $293,629 |
| TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2025 | Their institution | $197,466 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2019 | Their institution | $118,500 |
| Genentech, Inc. · A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients · 2020 | Their institution | $46,929 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2020 | Their institution | $45,518 |
| Genentech, Inc. · A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients · 2019 | Their institution | $45,292 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Melanoma Non-Inferiority Rela+Nivo Fdc Subq Vs. Rela+Nivo Fdc IV · 2024 | Their institution | $33,012 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2021 | Their institution | $32,656 |
| E.R. Squibb & Sons, L.L.C. · Phiii Stage 3/4 Resectable Mel Adj Rela+Nivo Vs Nivo - A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Relatlimab Andnivolumab Fixed-Dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma [ · 2023 | Their institution | $28,493 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Melanoma Non-Inferiority Rela+Nivo Fdc Subq Vs. Rela+Nivo Fdc IV · 2023 | Their institution | $25,737 |
| Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2019 | Their institution | $23,714 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open-Label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants With Previously Untreated Metastatic Or Unresectable Melanoma · 2025 | Their institution | $17,382 |
| Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2021 | Their institution | $17,225 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2022 | Their institution | $11,008 |
| Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2020 | Their institution | $10,260 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2020 | Their institution | $9,678 |
| TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2022 | Their institution | $7,269 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2021 | Their institution | $3,737 |
| Merck Sharp & Dohme LLC · A Phase II Trial of Mk3475 in Merkel Cell Carcinoma Mcc · 2022 | Their institution | $2,409 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2022 | Their institution | $1,827 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2023 | Their institution | $1,355 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2024 | Their institution | $575 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2022 | Their institution | $490 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open-Label Study of Nktr-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable Or Metastatic Melanoma · 2025 | Their institution | $373 |
| E.R. Squibb & Sons, L.L.C. · Phiii Stage 3 4 Resectable Mel Adj Rela Nivo Vs Nivo · 2021 | Their institution | $263 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2019 | Their institution | $149 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2023 | Their institution | $38 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1578645057
- Licence
- CA A61643California A61643: Current · expires 2028-08-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-20
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5725 W Las Positas Blvd, Pleasanton, CA, 94588